These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 17891370)

  • 61. Workflow and scan protocol considerations for integrated whole-body PET/MRI in oncology.
    Martinez-Möller A; Eiber M; Nekolla SG; Souvatzoglou M; Drzezga A; Ziegler S; Rummeny EJ; Schwaiger M; Beer AJ
    J Nucl Med; 2012 Sep; 53(9):1415-26. PubMed ID: 22879079
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Value analysis of postoperative staging imaging for asymptomatic, early-stage breast cancer: implications of clinical variation on utility and cost.
    Pellet AC; Erten MZ; James TA
    Am J Surg; 2016 Jun; 211(6):1084-8. PubMed ID: 26545344
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cost-effectiveness of PET and PET/computed tomography: a systematic review.
    Gerke O; Hermansson R; Hess S; Schifter S; Vach W; Høilund-Carlsen PF
    PET Clin; 2015 Jan; 10(1):105-24. PubMed ID: 25455883
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Whole-body MRI for the staging and follow-up of patients with metastasis.
    Schmidt GP; Reiser MF; Baur-Melnyk A
    Eur J Radiol; 2009 Jun; 70(3):393-400. PubMed ID: 19457631
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues.
    Pace L; Nicolai E; Luongo A; Aiello M; Catalano OA; Soricelli A; Salvatore M
    Eur J Radiol; 2014 Feb; 83(2):289-96. PubMed ID: 24331845
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cost-effectiveness analysis of strategies introducing integrated ¹⁸F-FDG PET/CT into the mediastinal lymph node staging of non-small-cell lung cancer.
    Han Y; Xiao H; Zhou Z; Yuan M; Zeng Y; Wu H; Fang Y
    Nucl Med Commun; 2015 Mar; 36(3):234-41. PubMed ID: 25460305
    [TBL] [Abstract][Full Text] [Related]  

  • 67. PET/MRI-knocking on the doors of the rich and famous.
    Beyer T; Hacker M; Goh V
    Br J Radiol; 2017 Aug; 90(1077):20170347. PubMed ID: 28707543
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Patient comfort during positron emission tomography/magnetic resonance and positron emission tomography/computed tomography examinations: subjective assessments with visual analog scales.
    Gückel B; Gatidis S; Enck P; Schäfer J; Bisdas S; Pfannenberg C; Schwenzer N
    Invest Radiol; 2015 Oct; 50(10):726-32. PubMed ID: 26039772
    [TBL] [Abstract][Full Text] [Related]  

  • 69. High-cost imaging in elderly patients with stage IV cancer: challenges for research, policy, and practice.
    Yabroff KR; Warren JL
    J Natl Cancer Inst; 2012 Aug; 104(15):1113-4. PubMed ID: 22851272
    [No Abstract]   [Full Text] [Related]  

  • 70. [Cost-benefit analysis of intraoperative 3D imaging].
    Hüfner T; Stübig T; Gösling T; Kendoff D; Geerling J; Krettek C
    Unfallchirurg; 2007 Jan; 110(1):14-21. PubMed ID: 17177043
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Whole-body MRI and PET/CT in tumor diagnosis].
    Schmidt GP; Schmid R; Hahn K; Reiser MF
    Radiologe; 2004 Nov; 44(11):1079-87. PubMed ID: 15558227
    [TBL] [Abstract][Full Text] [Related]  

  • 72. High-cost imaging in elderly patients with stage IV cancer.
    Hu YY; Kwok AC; Jiang W; Taback N; Loggers ET; Ting GV; Lipsitz SR; Weeks JC; Greenberg CC
    J Natl Cancer Inst; 2012 Aug; 104(15):1164-72. PubMed ID: 22851271
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Whole-body magnetic resonance imaging: a viable alternative to positron emission tomography/CT in the evaluation of neoplastic diseases.
    Hochhegger B; Irion K; Marchiori E
    J Bras Pneumol; 2010; 36(3):396. PubMed ID: 20625681
    [No Abstract]   [Full Text] [Related]  

  • 74. The value of diagnostic medical imaging.
    Bradley D; Bradley KE
    N C Med J; 2014; 75(2):121-5. PubMed ID: 24663134
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Importance of whole body MRI for staging of colorectal cancer].
    Schmidt G
    Radiologe; 2012 Jun; 52(6):537-44. PubMed ID: 22618626
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Additional Clinical Value for PET/MRI in Oncology: Moving Beyond Simple Diagnosis.
    Miles KA; Voo SA; Groves AM
    J Nucl Med; 2018 Jul; 59(7):1028-1032. PubMed ID: 29545379
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Whole-body hybrid PET/MRI: ready for clinical use?
    Ratib O; Beyer T
    Eur J Nucl Med Mol Imaging; 2011 Jun; 38(6):992-5. PubMed ID: 21465254
    [No Abstract]   [Full Text] [Related]  

  • 78. Positron emission tomography costs less to patients than conventional screening for malignancy in dermatomyositis.
    Kundrick A; Kirby J; Ba D; Leslie D; Olsen N; Foulke G
    Semin Arthritis Rheum; 2019 Aug; 49(1):140-144. PubMed ID: 30482435
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Whole-Body PET/MRI Applications in Pediatric Oncology.
    States LJ; Reid JR
    AJR Am J Roentgenol; 2020 Sep; 215(3):713-725. PubMed ID: 32755171
    [No Abstract]   [Full Text] [Related]  

  • 80. Diagnosis of meningeoma. A comparison of costs before CT, during CT and after introduction of MR imaging.
    Laurila J; Suramo I; Brommels M; Servo A; Kotikangas J; Standertskjöld-Nordenstam CG
    Acta Radiol; 2000 Nov; 41(6):539-43. PubMed ID: 11092472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.